The impact of positron emission tomography on primary tumour delineation and dosimetric outcome in intensity modulated radiotherapy of early T-stage nasopharyngeal carcinoma by Vincent W. C. Wu et al.
RESEARCH Open Access
The impact of positron emission
tomography on primary tumour delineation
and dosimetric outcome in intensity
modulated radiotherapy of early T-stage
nasopharyngeal carcinoma
Vincent W. C. Wu1*, Wan-shun Leung1,2, Kwun-lam Wong1, Ying-kit Chan1, Wing-lam Law1, Wing-kwan Leung1
and Yat-long Yu1
Abstract
Background: In intensity modulated radiotherapy (IMRT) of nasopharyngeal carcinoma (NPC), accurate delineation
of the gross tumour volume (GTV) is important. Image registration of CT and MRI has been routinely used in
treatment planning. With recent development of positron emission tomography (PET), the aims of this study were
to evaluate the impact of PET on GTV delineation and dosimetric outcome in IMRT of early stage NPC patients.
Methods: Twenty NPC patients with T1 or T2 disease treated by IMRT were recruited. For each patient, 2 sets of NP
GTVs were delineated separately, in which one set was performed using CT and MRI registration only (GTVCM), while
the other set was carried out using PET, CT and MRI information (GTVCMP). A 9-field IMRT plan was computed based
on the target volumes generated from CT and MRI (PTVCM). To assess the geometric difference between the GTVCM
and GTVCMP, GTV volumes and DICE similarity coefficient (DSC), which measured the geometrical similarity between
the two GTVs, were recorded. To evaluate the dosimetric impact, the Dmax, Dmin, Dmean and D95 of PTVs were obtained
from their dose volume histograms generated by the treatment planning system.
Results: The overall mean volume of GTVCMP was greater than GTVCM by 4.4 %, in which GTVCMP was slightly greater in
the T1 group but lower in the T2 group. The mean DSC of the whole group was 0.79 ± 0.05. Similar mean DSC values
were also obtained from the T1 and T2 groups separately. The dosimetric parameters of PTVCM fulfilled the planning
requirements. When applying this plan to the PTVCMP, the average Dmin (56.9 Gy) and D95 (68.6 Gy) of PTVCMP failed to
meet the dose requirements and demonstrated significant differences from the PTVCM (p = 0.001 and 0.016 respectively),
whereas the doses to GTVCMP did not show significant difference with the GTVCM.
Conclusion: In IMRT of early stage NPC, PET was an important imaging modality in radiotherapy planning so as to avoid
underdosing the PTV, although its effect on GTV delineation was not significant. It was recommended that PET images
should be included in the treatment planning of NPC patients.
Abbreviations: CT, Computed tomography; CTV, Clinical target volume; Dmax, Maximum dose; Dmin, Minimum dose;
DSC, DICE similarity coefficient; DVH, Dose volume histogram; GTV, Gross tumour volume; IMRT, Intensity modulated
radiotherapy; MLC, Multileaf collimator; MRI, Magnetic resonance imaging; NPC, Nasopharyngeal carcinoma; PET, Positron
emission tomography; PRV, Planning organ at risk volume; PTV, Planning target volume
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Background
Intensity modulated radiotherapy (IMRT) is now routinely
used to treat nasopharyngeal carcinoma (NPC) because of
its better dose conformity and steeper dose gradient at the
boundary of target volume. Several dosimetric studies
have proven that IMRT could improve the dose coverage
to the target volume with relatively lower dose to the
organs at risk (OARs) [1, 2]. Accurate delineation of the
gross tumour volume (GTV) becomes more important in
order to deliver effective dose coverage to the tumour
[3, 4]. It is because a slight discrepancy in target delin-
eation may cause underdose of the target volume and/
or overdose of the adjacent normal tissues leading to
uncontrolled primary tumour or unexpected toxicities
[5, 6]. To improve the accuracy of target delineation,
combining the findings from different imaging modalities
has been introduced in radiotherapy, which can provide
more comprehensive information about the tumour ex-
tension. Because of this, image registration between com-
puted tomography (CT) and magnetic resonance imaging
(MRI) has been routinely performed for the target delinea-
tion in NPC cases in local oncology departments. The
complementary roles of these two modalities are that CT
provides the geometry and electron density of the anatom-
ical structures for radiotherapy localization and treatment
planning while MRI is good at differentiating malignant
tumour from soft tissues [7]. The combination of CT and
MRI in target delineation of NPC patients has been
proven to be useful in defining the extension of tumour
involvement [8].
Apart from these imaging modalities, positron emission
tomography (PET) has recently emerged as a valuable im-
aging modality in oncology due to its unique functional im-
aging property which can detect early malignant changes of
cells [9]. The current clinical applications of PET in oncol-
ogy include diagnosis and staging. Despite PET images have
lower spatial resolution, it has the potential to further
improve target delineation when registered with CT or
MRI images and some positive results of PET in tumours
of the thoracic region have been reported [10–12]. For tar-
get delineation of head and neck cancers, the benefit of
PET is still controversial [7, 13], especially when this mo-
dality introduces radiation dose to staff and is relatively
more expensive. Therefore, the aims of this study were to
evaluate the impact of PET on GTV delineation in IMRT
of NPC patients and identify if there was any significant
dosimetric change in the target volumes after including it
in the treatment planning process.
Methods
Twenty adult NPC patients with early T-stages (T1 and
T2 according to AJCC 2007) treated by IMRT were
retrospectively recruited. The reason for excluding high
T-stages was because these tumours usually presented
with bony infiltration, of which PET was known to have
a poorer sensitivity [14]. Ethics approval was obtained
from the local hospital and associated institution. All
patients underwent imaging of the head and neck region
by CT, MRI and PET. The CT and PET were taken in
the same treatment position, whereas the MRI scan was
carried out with the patient in normal supine head
straight position. At the PET-CT unit, the patient was
injected with 18F-FDG about 45 min before the scan.
Immobilisation was applied using the tailor-made
thermoplastic shell. After taking the topogram, which
helped to define the scanning range from the vertex to
the upper chest level, CT acquisition with slice thickness
of 2.5 mm was performed. This was then followed by
the PET acquisition which covered the same scan range
of CT. The GTV delineation based on all the three im-
aging modalities (GTVCMP) was carried out following
the protocol of local department which was referenced
from the International Commission on Radiation Units
and Measurement Reports 50 and 62 guidelines [15, 16].
Registration of CT and PET images were first conducted,
and the result was then co-registered with the MRI
through rigid registration using the MIM software
(Version6.3.4, MIM Software Inc., US). The final GTV
was then delineated on the CT images based on the in-
formation obtained from the PET-MRI-CT registration.
Another GTV was delineated using registered images
of CT and MRI only (GTVCM) which was performed
using the same MIM software based on the same target
delineation protocol by a different clinician who was
blinded to the GTVCMP. An example of GTV delinea-
tion by the two methods is shown in Fig. 1. A routine
IMRT treatment which consisted of 9 equal spaced IM
beams with 6 MV and dynamic multileaf collimators
(MLC) was then computed using GTVCM as the only
target with the GTVCMP and PTVCMP being switched
off. 70 Gy in 35 fractions was prescribed to the PTV
which was created by adding 1 cm to the GTV. PTVCM
was created from GTVCM while PTVCMP was created
from GTVCMP. The dose requirements of the target
volume were that at least 70 Gy should cover 95 % of
PTV and 100 % of GTV. The organs at risks (OARs)
were delineated and planning organs at risk volume
(PRVs) were created for the more critical structures
such as brain stem, spinal cord and optic chiasm by
adding 1 mm in all directions, The planning objectives
and dose constraints of the targets and OARs were
based on the local planning protocol which was refer-
enced from the Radiation Therapy Oncology Group
(RTOG) 0225 protocol.
For each patient, the GTVCMP and GTVCM volumes
were recorded. DICE similarity coefficient (DSC),
which was generated by the MIM software, was used to
evaluate the geometrical difference between GTVCMP
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and GTVCM. DSC was defined by (Vp, V1) = 2|Vp∩V1|/
|Vp| + |V1|, where Vp and V1 were the volumes of
GTVCMP and GTVCM respectively and ∩ was the inter-
section. A value of 1.0 would indicate perfect volume
match between the two GTVs, whereas 0 would imply
no overlapping of volume exist. For dosimetric analysis
of the target volume, PTV was the main focus apart
from GTV because PTV dose would be more clinically
relevant and expected to demonstrate more obvious
difference between the two delineation methods. The
maximum (Dmax), minimum (Dmin), mean doses (Dmean),
and dose received by 95 % volume (D95) of PTV; and Dmax
Dmin, and Dmean of GTV were obtained from the their
respective dose volume histograms. The average values of
volumetric and dosimetric parameters from each delinea-
tion method were calculated for comparison. Furthermore,
the difference in GTV geometry between T1 and T2 patient
groups were also evaluated. All data were tested for the
normality by Shapiro-Wilk test. Paired t-test or Wilcoxon
signed-rank test was used to compare the differences
between the two delineation methods depending on the
normality of data, whereas Mann–Whitney U test was used
to compare the differences between T1 and T2 patient
Table 1 Stage distribution of the sample group (n = 20)
Staginga No (%)
T1N0M0 2 (10 %)
T1N1M0 5 (25 %)
T1N2M0 5 (25 %)
T2N0M0 3 (15 %)
T2N1M0 2 (10 %)
T2N2M0 1 (5 %)
T2N3M0 2 (10 %)
aAmerican Joint Committee on Cancer 2007 staging system
Table 2 Volume comparison between GTVCM and GTVCMP
GTVCM (cm
3) GTVCMP (cm
3) Wilcoxon signed-rank test
Group Mean ± SD Mean ± SD p value
T1 (n = 12) 9.8 ± 3.7 11.5 ± 5.5 0.329
T2 (n = 8) 21.9 ± 8.7 19.4 ± 4.9 0.591
All (n = 20) 12.9 ± 7.7 13.5 ± 6.5 0.232
Fig. 1 An example of difference in GTV delineation between GTVCM (Red) and GTVCMP (Green)
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groups. All statistical tests were performed using Statistical
Package for Social Science (SPSS) version 22 (IBM).
Results
Sixty percent of patients (n = 12) presented with T-1
stage and 40 % of them were T2 (Table 1). The mean
GTV and PTV volumes of the T2 group were greater
than those of T1 group by 55 % and 40 % respectively.
With regard to the GTV geometry generated by the two
delineation methods, the overall mean GTVCMP was
greater than GTVCM (13.5 cm
3 vs 12.9 cm3) and their dif-
ference did not reach statistical significance (p = 0.232)
(Table 2). The GTVCMP was slightly greater in the T1 group
but lower in the T2 group. The mean DSC value of the
whole group obtained by comparing the volumes of
GTVCMP and GTVCM was 0.79 ± 0.05 (Table 3). Similar
mean DSC values were also obtained from the T1 and T2
groups separately, and there was no significant difference
between these two T-stage groups (p = 0.691).
For all treatment plans, the doses to the OARs met
the dose requirements as stipulated in the planning
protocol. Since the plans were computed based on
PTVCM, the dosimetric parameters of PTVCM (includ-
ing those of GTVCM) fulfilled the planning require-
ments, in which at least 95 % of PTV received 70 Gy,
and the Dmax and Dmin were kept below 77 Gy and
above 63 Gy respectively. When applying this plan to
the PTVCMP, the Dmin (56.9 Gy) and D95 (68.6 Gy) of
PTVCMP failed to meet the above-stated dose require-
ments and demonstrated significant differences from the
PTVCM (p = 0.001 and 0.016 respectively) (Table 4). The
difference in target dose coverage between PTVCMP and
PTVCM was also demonstrated by their average DVHs
(Fig. 2). Nevertheless, the doses to GTVCMP did not show
significant difference with the GTVCM.
Discussion
As far as volumetric analysis of the GTV was concerned,
the current study revealed that there was only mild
impact of PET on GTV delineation for the early stage
primary NP tumour. The volume differences between
GTVCM and GTVCMP were not significant with an over-
all mean difference of about 4.4 %. Previous studies on
moderate to late stages (II to IV) head and neck cancers
reported that there was a decrease in GTV volume de-
lineation with PET when compared to those with either
CT or MRI [17, 18]. Our study showed similar result for
the T2 cases but the difference was not significant. In
addition, as the overall mean DSC of GTV between the
two delineation methods was close to 0.8, it indicated
that the difference in GTV shape between the two delin-
eation methods was not great. This implied that the
introduction of PET did not lead to dramatic change of
the GTV geometry. When comparing the results be-
tween the T1 and T2 groups, it was logical to see that
the average GTV volume of T2 group was significant lar-
ger than that of the T1 group due to the relatively more
extensive tumour invasion. However, when analysing the
impact of PET on these two T-stage groups, they did not
showed any obvious difference, which was reflected by
the GTV volume and DSC comparisons. Since PET was
a functional imaging tool and effective in detecting early
malignant changes, it was able to pick up microscopic
spread around the primary tumour which might not be
detected by MRI or CT. Taking reference from other
tumours [19–21], for early stage of NPC, the primary
tumour was relatively small and the chance of extensive
microscopic spread was lower compared to more ad-
vanced tumours. The contribution by PET to provide
extra tumour information would not be much, and could
be one of the reasons that resulted in a relatively mild
change of GTV geometry.
Unlike the volumetric analysis results, the dosimetric
impact of PET was more significant, especially on the PTV
dose. Despite the GTV doses did not show significant dif-
ference between the two delineation methods, the Dmin and
Table 4 Comparison of GTV and PTV doses between plans with and without PET in target delineation
GTV PTV
GTVCM GTVCMP PTVCM PTVCMP
Mean ± SD Mean ± SD P value* Mean ± SD Mean ± SD P value*
Dmin (Gy) 70.7 ± 7.6 70.6 ± 5.7 0.895 67.9 ± 4.5 56.9 ± 6.6 0.001
Dmean (Gy) 72.2 ± 2.9 72.2 ± 3.7 0.796 72.2 ± 2.6 71.9 ± 1.2 0.369
Dmax (Gy) 73.7 ± 2.2 73.7 ± 1.3 0.981 74.5 ± 2.9 74.4 ± 0.9 0.548
D95 (Gy) – – – 71.1 ± 2.1 68.6 ± 2.6 0.016
*Wilcoxon signed-rank test
Table 3 DICE similarity coefficient (DSC) results by comparing
GTVCM and GTVCMP
DSC Mann–Whitney U test
Group Mean ± SD p value
T1 (n = 12) 0.79 ± 0.05 0.691
T2 (n = 8) 0.78 ± 0.04
All (n = 20) 0.79 ± 0.05
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Fig. 3 An example of IMRT plan showing the dose distribution at one of the CT slices. The plan was computed based on the PTVCM
(Red). The black arrows indicate the regions of PTVCMP (Cyan) receiving less than 95 % isodose level (indicated by the red arrow)
Fig. 2 Average dose volume histograms of PTVCMP and PTVCM
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D95 of PTVCMP were significantly lower than the PTVCM
and did not meet the dose requirement. This implied that
there were distinct underdose regions in the PTVCMP and
might not be acceptable clinically. The reason for such dif-
ference in PTV coverage was because the discrepancy in
target delineation was magnified in the PTV which was
expanded from the GTV. After including the PET informa-
tion, considerable portion of the PTVCMP was found out-
side the original PTVCM (Fig. 3). Since the treatment plan
was computed according to the PTVCM, these PTVCMP re-
gions outside PTVCM would not be adequately covered by
the prescribed dose (e.g. 95 % isodose level) and therefore
might not receive adequate dose. The reason that this dosi-
metric difference did not appear in the GTV was because
the volume of the GTVs was relatively small and so were
their differences.
PET is a more expansive imaging modality that involves
radiation exposure to radiographers during patient posi-
tioning. Its omission can be justified if there were no added
value for radiotherapy treatment planning. In the radiother-
apy of early stages of NPC, although the effect of PET on
the overall GTV geometry was not significant, there was
impact on the dose distribution of the PTV. Our study
demonstrated the treatment plans produced just from the
CT and MRI was not adequate to cover the PTV generated
from CT, MRI and PET, which was believed to be the more
accurately delineated target. Our result echoed the report
from Graf et al. [22] who reported that PET had significant
impact on stereotactic radiotherapy of malignant cranial
based tumours. Though PET was reported to be less satis-
factory in detecting bone infiltration, it is still worth to
extend this study to the more extensive tumour so as to
obtain a more comprehensive picture about the impact of
PET on all NPC patients.
Conclusion
In IMRT of early stage NPC, in addition to CT and MRI,
PET was an important imaging modality in radiotherapy
planning so as to avoid underdosing the PTV, although
its effect on GTV delineation was not significant. It was
recommended that PET images should be included in
the treatment planning for this group of NPC patients.
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